American Association for Cancer Research
Browse
23266066cir190373-sup-222655_2_supp_5823317_q0m0h8.pdf (58.5 kB)

Figure S4 from Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer

Download (58.5 kB)
journal contribution
posted on 2023-04-04, 00:40 authored by Jian Ye, Bradley N. Mills, Tony Zhao, Booyeon J. Han, Joseph D. Murphy, Ankit P. Patel, Carl J. Johnston, Edith M. Lord, Brian A. Belt, David C. Linehan, Scott A. Gerber

Supplemental figure 4

Funding

NIH

Translational Research Grant

History

ARTICLE ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) continues to have a dismal prognosis, in part, due to ineffective treatment strategies. The efficacy of some chemotherapies and especially radiotherapy is mediated partially by the immune system. Therefore, we hypothesized that profiling the immune response following chemotherapy and/or irradiation can be used as a readout for treatment efficacy but also to help identify optimal therapeutic schedules for PDAC. Using murine models of PDAC, we demonstrated that concurrent administration of stereotactic body radiotherapy (SBRT) and a modified dose of FOLFIRINOX (mFX) resulted in superior tumor control when compared with single or sequential treatment groups. Importantly, this combined treatment schedule enhanced the magnitude of immunogenic cell death, which in turn amplified tumor antigen presentation by dendritic cells and intratumoral CD8+ T-cell infiltration. Concurrent therapy also resulted in systemic immunity contributing to the control of established metastases. These findings provide a rationale for pursuing concurrent treatment schedules of SBRT with mFX in PDAC.